IL300364A - immunogenic substances - Google Patents

immunogenic substances

Info

Publication number
IL300364A
IL300364A IL300364A IL30036423A IL300364A IL 300364 A IL300364 A IL 300364A IL 300364 A IL300364 A IL 300364A IL 30036423 A IL30036423 A IL 30036423A IL 300364 A IL300364 A IL 300364A
Authority
IL
Israel
Prior art keywords
asyn
disease
peptide
amino acid
antigenic peptide
Prior art date
Application number
IL300364A
Other languages
English (en)
Hebrew (he)
Inventor
Dorian Winter
Gunther Staffler
Gergana Galabova
Eva Mihailovska
Petra Gruber
Katja Balazs
Original Assignee
Ac Immune Sa
Dorian Winter
Gunther Staffler
Gergana Galabova
Eva Mihailovska
Petra Gruber
Katja Balazs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa, Dorian Winter, Gunther Staffler, Gergana Galabova, Eva Mihailovska, Petra Gruber, Katja Balazs filed Critical Ac Immune Sa
Publication of IL300364A publication Critical patent/IL300364A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
IL300364A 2020-08-04 2021-08-04 immunogenic substances IL300364A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20189425 2020-08-04
PCT/EP2021/071778 WO2022029181A1 (en) 2020-08-04 2021-08-04 Immunogenic compounds

Publications (1)

Publication Number Publication Date
IL300364A true IL300364A (en) 2023-04-01

Family

ID=72178339

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300364A IL300364A (en) 2020-08-04 2021-08-04 immunogenic substances

Country Status (10)

Country Link
US (1) US20230287050A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192493A1 (cg-RX-API-DMAC7.html)
JP (1) JP7898188B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230044524A (cg-RX-API-DMAC7.html)
CN (1) CN116261464A (cg-RX-API-DMAC7.html)
AU (1) AU2021322080A1 (cg-RX-API-DMAC7.html)
CA (1) CA3185563A1 (cg-RX-API-DMAC7.html)
IL (1) IL300364A (cg-RX-API-DMAC7.html)
MX (1) MX2023001483A (cg-RX-API-DMAC7.html)
WO (1) WO2022029181A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314865A (en) * 2022-02-09 2024-10-01 Ac Immune Sa Anti-alpha-synuclein therapeutic vaccines
KR20250135293A (ko) 2023-01-26 2025-09-12 에이씨 이뮨 에스에이 리포좀 구조체
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2361928T3 (en) 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
PL2723379T3 (pl) * 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
CA3003943A1 (en) 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient
JP7136790B2 (ja) * 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
JP2021508672A (ja) * 2017-06-16 2021-03-11 ユナイテッド ニューロサイエンスUnited Neuroscience シヌクレイノパチーの治療のためのアルファ−シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤
WO2021055881A1 (en) * 2019-09-20 2021-03-25 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof

Also Published As

Publication number Publication date
CN116261464A (zh) 2023-06-13
JP7898188B2 (ja) 2026-07-31
US20230287050A1 (en) 2023-09-14
WO2022029181A1 (en) 2022-02-10
CA3185563A1 (en) 2022-02-10
AU2021322080A1 (en) 2023-02-23
MX2023001483A (es) 2023-03-08
KR20230044524A (ko) 2023-04-04
EP4192493A1 (en) 2023-06-14
JP2023536497A (ja) 2023-08-25

Similar Documents

Publication Publication Date Title
US20230201320A1 (en) Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy
US8828942B2 (en) Means for treating synucleinopathies
KR20110036808A (ko) 베타-아밀로이드증을 치료하기 위한 화합물
US20230287050A1 (en) Immunogenic Compounds
US20070172496A1 (en) Conjugates of amyloid proteins as vaccines for amyloid-related diseases
US20150306194A1 (en) Method for treating a synucleiopathy
US20250152684A1 (en) Anti-Alpha-Synuclein Therapeutic Vaccines
TW202438516A (zh) TAU及β類澱粉肽免疫原組合物及相關方法
EA048154B1 (ru) Иммуногенные соединения
HK40087814A (en) Immunogenic compounds
TW202142551A (zh) 針對pcsk9胜肽免疫原及其預防和治療pcsk9介導疾病的製劑
EA051687B1 (ru) Терапевтические вакцины против альфа-синуклеина
CN118660717A (zh) 抗α-突触核蛋白的治疗性疫苗
WO2024015611A2 (en) Tau peptide immunogen constructs
HK1152470B (en) Peptides for treating beta-amyloidoses